MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer
Third-generation EGFR tyrosine kinase inhibitors (TKIs), such as osimertinib, have demonstrated efficacy in patients with -mutant non-small-cell lung cancer; however, almost all patients will eventually relapse. Amivantamab is an EGFR-MET bispecific antibody with immune cell-directing activity that...
Gespeichert in:
| Veröffentlicht in: | Future oncology (London, England) Jg. 18; H. 6; S. 639 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
England
01.02.2022
|
| Schlagworte: | |
| ISSN: | 1744-8301, 1744-8301 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Third-generation EGFR tyrosine kinase inhibitors (TKIs), such as osimertinib, have demonstrated efficacy in patients with
-mutant non-small-cell lung cancer; however, almost all patients will eventually relapse. Amivantamab is an EGFR-MET bispecific antibody with immune cell-directing activity that targets activating and resistance
mutations and
mutations and amplifications. In the ongoing CHRYSALIS study (NCT02609776), amivantamab in combination with lazertinib, a potent, brain-penetrant third-generation EGFR TKI, demonstrated antitumor activity in the treatment-naive and osimertinib-relapsed setting. Here the authors present the methodology for the MARIPOSA study (NCT04487080), a phase 3, multicenter, randomized study designed to compare the efficacy and safety of amivantamab and lazertinib combination therapy versus single-agent osimertinib as first-line treatment for
-mutant non-small-cell lung cancer. |
|---|---|
| AbstractList | Third-generation EGFR tyrosine kinase inhibitors (TKIs), such as osimertinib, have demonstrated efficacy in patients with EGFR-mutant non-small-cell lung cancer; however, almost all patients will eventually relapse. Amivantamab is an EGFR-MET bispecific antibody with immune cell-directing activity that targets activating and resistance EGFR mutations and MET mutations and amplifications. In the ongoing CHRYSALIS study (NCT02609776), amivantamab in combination with lazertinib, a potent, brain-penetrant third-generation EGFR TKI, demonstrated antitumor activity in the treatment-naive and osimertinib-relapsed setting. Here the authors present the methodology for the MARIPOSA study (NCT04487080), a phase 3, multicenter, randomized study designed to compare the efficacy and safety of amivantamab and lazertinib combination therapy versus single-agent osimertinib as first-line treatment for EGFR-mutant non-small-cell lung cancer.Third-generation EGFR tyrosine kinase inhibitors (TKIs), such as osimertinib, have demonstrated efficacy in patients with EGFR-mutant non-small-cell lung cancer; however, almost all patients will eventually relapse. Amivantamab is an EGFR-MET bispecific antibody with immune cell-directing activity that targets activating and resistance EGFR mutations and MET mutations and amplifications. In the ongoing CHRYSALIS study (NCT02609776), amivantamab in combination with lazertinib, a potent, brain-penetrant third-generation EGFR TKI, demonstrated antitumor activity in the treatment-naive and osimertinib-relapsed setting. Here the authors present the methodology for the MARIPOSA study (NCT04487080), a phase 3, multicenter, randomized study designed to compare the efficacy and safety of amivantamab and lazertinib combination therapy versus single-agent osimertinib as first-line treatment for EGFR-mutant non-small-cell lung cancer. Third-generation EGFR tyrosine kinase inhibitors (TKIs), such as osimertinib, have demonstrated efficacy in patients with -mutant non-small-cell lung cancer; however, almost all patients will eventually relapse. Amivantamab is an EGFR-MET bispecific antibody with immune cell-directing activity that targets activating and resistance mutations and mutations and amplifications. In the ongoing CHRYSALIS study (NCT02609776), amivantamab in combination with lazertinib, a potent, brain-penetrant third-generation EGFR TKI, demonstrated antitumor activity in the treatment-naive and osimertinib-relapsed setting. Here the authors present the methodology for the MARIPOSA study (NCT04487080), a phase 3, multicenter, randomized study designed to compare the efficacy and safety of amivantamab and lazertinib combination therapy versus single-agent osimertinib as first-line treatment for -mutant non-small-cell lung cancer. |
| Author | Cho, Byoung Chul Sethi, Seema N Thomas, Michael Spira, Alexander I Besse, Benjamin Hayashi, Hidetoshi Sun, Tao Shreeve, S Martin Lu, Shun Felip, Enriqueta Martinez, Melissa |
| Author_xml | – sequence: 1 givenname: Byoung Chul orcidid: 0000-0002-5562-270X surname: Cho fullname: Cho, Byoung Chul organization: Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea – sequence: 2 givenname: Enriqueta surname: Felip fullname: Felip, Enriqueta organization: Vall d'Hebron University, Vall d'Hebron Institute of Oncology, Barcelona, Spain – sequence: 3 givenname: Hidetoshi surname: Hayashi fullname: Hayashi, Hidetoshi organization: Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan – sequence: 4 givenname: Michael surname: Thomas fullname: Thomas, Michael organization: Thoraxklinik & National Center for Tumor Diseases at Heidelberg University Hospital, Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), member of the German Center for Lung Research (DZL) – sequence: 5 givenname: Shun surname: Lu fullname: Lu, Shun organization: Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai – sequence: 6 givenname: Benjamin surname: Besse fullname: Besse, Benjamin organization: Cancer Medicine Department, Gustave Roussy, Villejuif, France & Paris-Saclay University, Orsay, France – sequence: 7 givenname: Tao surname: Sun fullname: Sun, Tao organization: Janssen Research & Development, USA – sequence: 8 givenname: Melissa surname: Martinez fullname: Martinez, Melissa organization: Janssen Research & Development, USA – sequence: 9 givenname: Seema N surname: Sethi fullname: Sethi, Seema N organization: Janssen Research & Development, USA – sequence: 10 givenname: S Martin surname: Shreeve fullname: Shreeve, S Martin organization: Janssen Research & Development, USA – sequence: 11 givenname: Alexander I surname: Spira fullname: Spira, Alexander I organization: US Oncology Research, The Woodlands, TX, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34911336$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNUM1Kw0AYXKRif_ToVfYoyOr-JJvEWyltLVQqVc_lS_qtriSbmk0KFXyXPkufzIoteJphmBmG6ZKWKx0Scin4rZQiujOlY5JLwXgi1QnpiCgIWKy4aP3jbdL1_oPzIFIhPyNtFSRCKKU75PuxP588zZ7793T1Dh6por5ulhtaGmps5WuWW4cUCrsGV0MB6W57s9vm8IVVbZ1N6Ror33haelscJevocDyas6Kp9yG6X8x8AXnOMsxzmjfujWbgMqzOyamB3OPFAXvkdTR8GTyw6Ww8GfSnLFNaKYZaG5OiSbgBhFgIA0obHslIKp2mQWiiDISOJSZGAA_BiGUYI5cYxgEKLXvk-q93VZWfDfp6UVj_OwYclo1fSC14wsMwjPfWq4O1SQtcLlaVLaDaLI6XyR9kdXFw |
| CitedBy_id | crossref_primary_10_1002_cai2_56 crossref_primary_10_3389_fonc_2024_1363069 crossref_primary_10_3390_cancers14143337 crossref_primary_10_1158_1078_0432_CCR_23_0737 crossref_primary_10_1016_j_jtho_2024_11_032 crossref_primary_10_33590_emj_10113934 crossref_primary_10_1007_s10637_023_01337_8 crossref_primary_10_1038_s41598_024_56046_w crossref_primary_10_1007_s11864_022_01022_7 crossref_primary_10_3390_cancers15030629 crossref_primary_10_3389_fpubh_2022_911377 crossref_primary_10_2147_LCTT_S443099 crossref_primary_10_1038_s41392_023_01589_z crossref_primary_10_3390_cancers15205009 crossref_primary_10_3390_biomedicines11041141 crossref_primary_10_1002_ijc_35512 crossref_primary_10_3390_ijms24129855 crossref_primary_10_1007_s40487_022_00216_1 crossref_primary_10_1016_j_clcc_2024_08_003 crossref_primary_10_1016_j_bulcan_2025_02_024 crossref_primary_10_3390_ijms24065858 crossref_primary_10_1016_j_cpccr_2025_100374 crossref_primary_10_1016_j_cllc_2022_07_019 crossref_primary_10_3390_cancers15123162 crossref_primary_10_3390_biomedicines10092109 crossref_primary_10_1016_j_lungcan_2024_107509 crossref_primary_10_2147_LCTT_S467169 crossref_primary_10_3390_ijms24098212 crossref_primary_10_1186_s12943_025_02390_y crossref_primary_10_1186_s40364_024_00566_0 crossref_primary_10_1007_s11684_022_0976_4 crossref_primary_10_1186_s43556_022_00107_x crossref_primary_10_1016_j_molstruc_2025_142326 crossref_primary_10_1016_j_critrevonc_2024_104295 crossref_primary_10_1016_j_lungcan_2023_107213 crossref_primary_10_1186_s42047_025_00177_5 crossref_primary_10_3389_fimmu_2024_1366260 crossref_primary_10_3390_cancers16061079 crossref_primary_10_3390_ijms25116109 crossref_primary_10_1016_j_critrevonc_2025_104748 crossref_primary_10_1186_s13045_022_01391_4 crossref_primary_10_1016_j_lungcan_2025_108629 crossref_primary_10_1016_j_cyto_2024_156802 crossref_primary_10_1177_17588359221144099 crossref_primary_10_1177_10781552251358871 crossref_primary_10_1080_14737140_2022_2116004 crossref_primary_10_1186_s13046_023_02866_z crossref_primary_10_1016_j_jtocrr_2024_100779 crossref_primary_10_1016_j_nantod_2023_101819 crossref_primary_10_3390_cancers15112899 crossref_primary_10_1183_20734735_0039_2024 crossref_primary_10_3389_fonc_2022_952939 crossref_primary_10_3390_ph16101461 crossref_primary_10_3390_pharmaceutics15061604 crossref_primary_10_1016_j_biopha_2022_113959 crossref_primary_10_3390_cancers16162862 crossref_primary_10_1177_23247096241300929 crossref_primary_10_1016_j_amolm_2025_100073 crossref_primary_10_3389_fonc_2022_902967 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.2217/fon-2021-0923 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1744-8301 |
| ExternalDocumentID | 34911336 |
| Genre | Clinical Trial Protocol Journal Article |
| GrantInformation_xml | – fundername: Janssen Research & Development LLC |
| GroupedDBID | --- 0R~ 29H 3V. 4.4 53G 5GY 70G 7X7 88E 8AO 8FI 8FJ AAWTL ABJNI ABUWG ACGFS ACWKX ADBBV AENEX AFFYO AFKRA AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS BENPR BPHCQ BVXVI CCPQU CGR CS3 CUY CVF DU5 EBS ECM EHMNL EIF EJD F5P FYUFA H13 HMCUK HZ~ IAO IEA IHR ITC K-O M1P M4Z MV1 NPM NTCAX O9- OVD P2P PQQKQ PROAC PSQYO RFM RPM TDBHL TEORI TFL TFMDE TMEDX UKHRP 7X8 AAWFG ABNDM |
| ID | FETCH-LOGICAL-c3633-e66ffbef90faea811fa36f0727236bb45f7ca1682e9f1a05af1d58e02e584e162 |
| IEDL.DBID | 7X8 |
| ISSN | 1744-8301 |
| IngestDate | Thu Oct 02 09:57:16 EDT 2025 Thu Jan 02 22:42:34 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | amivantamab tyrosine kinase inhibitors EGFR mutations lazertinib non-small-cell lung cancer |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3633-e66ffbef90faea811fa36f0727236bb45f7ca1682e9f1a05af1d58e02e584e162 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 |
| ORCID | 0000-0002-5562-270X |
| OpenAccessLink | https://ir.ymlib.yonsei.ac.kr/handle/22282913/191236 |
| PMID | 34911336 |
| PQID | 2610905558 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2610905558 pubmed_primary_34911336 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-02-01 |
| PublicationDateYYYYMMDD | 2022-02-01 |
| PublicationDate_xml | – month: 02 year: 2022 text: 2022-02-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Future oncology (London, England) |
| PublicationTitleAlternate | Future Oncol |
| PublicationYear | 2022 |
| SSID | ssj0047350 |
| Score | 2.5474489 |
| Snippet | Third-generation EGFR tyrosine kinase inhibitors (TKIs), such as osimertinib, have demonstrated efficacy in patients with
-mutant non-small-cell lung cancer;... Third-generation EGFR tyrosine kinase inhibitors (TKIs), such as osimertinib, have demonstrated efficacy in patients with EGFR-mutant non-small-cell lung... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 639 |
| SubjectTerms | Acrylamides - adverse effects Acrylamides - therapeutic use Adolescent Adult Aniline Compounds - adverse effects Aniline Compounds - therapeutic use Antibodies, Bispecific - adverse effects Antibodies, Bispecific - therapeutic use Antineoplastic Agents, Immunological - adverse effects Antineoplastic Agents, Immunological - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Clinical Trials, Phase III as Topic ErbB Receptors - antagonists & inhibitors ErbB Receptors - genetics Humans Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - pathology Morpholines - adverse effects Morpholines - therapeutic use Multicenter Studies as Topic Mutation Neoplasm Metastasis Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Pyrazoles - adverse effects Pyrazoles - therapeutic use Pyrimidines - adverse effects Pyrimidines - therapeutic use Randomized Controlled Trials as Topic Research Design Young Adult |
| Title | MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/34911336 https://www.proquest.com/docview/2610905558 |
| Volume | 18 |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3JTsMwELXYhLiw74uMxA1ZJHbipFxQhShwaKlYpN4qJ_WISFlK03KAn2cmTeGEhMQlBytRvIzHz37jeYydaQCpfAeEpNnkqdAK43m-sLHVOooDR4dRJTYRdDphr9fo1gduZR1WOfOJlaMeFDGdkV9IygteZae6Gr4JUo0idrWW0JhniwqhDIV0Bb1vFoFUdesLkZ4I0ZKnOTYlovALKHI0EIlb6QYpFf2GLqtVprX23_qts9UaX_Lm1CA22JzNN9lyu2bQt9hnu_l43314al7y4SuuYFzxKsMsL4BDglBQEO7kJiOGaGwyE_FznpoPCr_Ok4hTFMek5EWZZLOiJOc3t61HkU1IkZjn2OYyM2kqiBTgKXoTHpNtjbbZS-vm-fpO1AIMIlZaKYHDBRBZaDhgrAldF4zS4BB3q3QUeT4EsXF1KG0DXOP4BtyBH1pHWoQ11tVyhy3gT-0e4xJfHAykDRBgeJHrmIASwaG_iF3ALSbss9NZt_bRwKmCJrfFpOz_dOw-252OTX84zcTRVx76aqX0wR--PmQrkq4uVBHXR2wRcHrbY7YUv4-TcnRSWQ4-O932F5dazWs |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=MARIPOSA%3A+phase+3+study+of+first-line+amivantamab%C2%A0%2B%C2%A0lazertinib+versus+osimertinib+in+EGFR-mutant+non-small-cell+lung+cancer&rft.jtitle=Future+oncology+%28London%2C+England%29&rft.au=Cho%2C+Byoung+Chul&rft.au=Felip%2C+Enriqueta&rft.au=Hayashi%2C+Hidetoshi&rft.au=Thomas%2C+Michael&rft.date=2022-02-01&rft.eissn=1744-8301&rft.volume=18&rft.issue=6&rft.spage=639&rft_id=info:doi/10.2217%2Ffon-2021-0923&rft_id=info%3Apmid%2F34911336&rft_id=info%3Apmid%2F34911336&rft.externalDocID=34911336 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1744-8301&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1744-8301&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1744-8301&client=summon |